English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Monday, November 1, 2021
エーザイとPRISM BioLab共同創製のCBP/β-catenin 阻害剤 E7386 について、臨床における POC(Proof of Concept:創薬概念の検証)を達成
The CREB-binding protein (CBP)/beta-catenin inhibitor E7386, co-created by Eisai and PRISM BioLab, achieved the clinical POC (Proof of Concept)
Monday, October 18, 2021
エーザイとMSD、「レンビマ(R)」と「キイトルーダ(R)」の併用療法について進行性腎細胞がんおよび進行性子宮内膜がんに関する承認勧告を欧州医薬品委員会より受領
Eisai and Merck & Co., Inc. (Kenilworth, N.J.) Receive Positive EU CHMP Opinions for LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in Two Different Types of Cancer
Tuesday, September 28, 2021
Eisai Initiates Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab (BAN2401) for Early Alzheimer's Disease Under the Accelerated Approval Pathway
Monday, September 27, 2021
アッヴィとエーザイ、ヒュミラについて潰瘍性大腸炎に係る用法・用量において成人に対する高用量と小児の追加承認を取得
Eisai: Fully Human Anti-TNFalpha Monoclonal Antibody HUMIRA Obtains Additional Approval
Wednesday, September 15, 2021
エーザイ、国際的な環境イニシアチブ「RE100」に加盟
Tuesday, September 14, 2021
Eisai to Join The Global Environmental Initiative "RE100"
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO Virtual Congress 2021

Copyright © 2021 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575